GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » EBIT per Share
中文

Sangui Biotech International (Sangui Biotech International) EBIT per Share

: $0.00 (TTM As of Mar. 2023)
View and export this data going back to . Start your Free Trial

Sangui Biotech International's EBIT per Share for the three months ended in Mar. 2023 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sangui Biotech International's EBIT per Share or its related term are showing as below:

SGBI's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Sangui Biotech International's EBIT for the three months ended in Mar. 2023 was $-0.03 Mil.

Sangui Biotech International EBIT per Share Historical Data

The historical data trend for Sangui Biotech International's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sangui Biotech International EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sangui Biotech International's EBIT per Share for the fiscal year that ended in Jun. 2022 is calculated as

EBIT per Share(A: Jun. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.044/208.605
=-0.00

Sangui Biotech International's EBIT per Share for the quarter that ended in Mar. 2023 is calculated as

EBIT per Share(Q: Mar. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.033/209.956
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangui Biotech International  (OTCPK:SGBI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sangui Biotech International EBIT per Share Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » EBIT per Share
Comparable Companies
SKYI BBBT DMKPQ CSTF CENBF ENDPQ PHBI THCT DKSC BLMS ZTS XTER:MRK TSE:4502 NSE:SUNPHARMA LSE:HLN VTRS XTAE:TEVA TSE:4507 XSWX:SDZ NBIX
Traded in Other Exchanges
SBH:Germany
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Website
http://www.sanguibiotech.com
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines